INKT - NASDAQ
MiNK Therapeutics, Inc.
$12.76
+1.4%MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
At a Glance
Live SnapshotMiNK Therapeutics, Inc. Management Team
Ms. Eleni Chantzoura Ph.D.
Director & Head of Discovery
Dr. Garo H. Armen Ph.D.
Executive Chairman
Dr. Jennifer S. Buell Ph.D.
President, Chief Executive Officer & Director
Compensation
$453,686
Ms. Christine M. Klaskin
Treasurer and Principal Financial & Accounting Officer
Compensation
$29,822
MiNK Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $607K and sold $94K worth of INKT shares, resulting in $513K of net buying activity.
3 Months
0
0.00
500
6.62K
-7K
-$7K
3-6 Months
0
0.00
500
5.42K
-5K
-$5K
6-9 Months
34.4K
527.68K
5.4K
82.19K
+445K
+$445K
9-12 Months
5.7K
79.42K
0
0.00
+79K
+$79K
Top Buyers
Buell Jennifer
Officer: Chief Executive Officer
$280K
Corvese Brian
Director
$67K
Ryan Barbara
Director
$67K
Behner Peter
Director
$66K
Wiinberg Ulf
Director
$64K
Top Sellers
Buell Jennifer
Officer: Chief Executive Officer
$82K
Ryan Barbara
Director
$12K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $513K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers vs. 2 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
INKT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 17, 2026 | 2026 | |
DEF 14A DEF 14A 2024 N/A | April 30, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2025 N/A | December 20, 2024 | January 17, 2025 | 2025 | |
DEF 14A DEF 14A 2023 N/A | April 29, 2024 | December 31, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | May 01, 2023 | December 31, 2022 | 2022 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 08, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.